Abstract
Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 67-71 |
| Number of pages | 5 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 112 |
| DOIs | |
| Publication status | Published - Apr 1 2017 |
Fingerprint
Keywords
- Outcomes
- Small cell lung cancer
- Stereotactic ablative radiotherapy
- Toxicity
ASJC Scopus subject areas
- Hematology
- Oncology
- Geriatrics and Gerontology
Cite this
Stage-I small cell lung cancer : A new potential option for stereotactic ablative radiation therapy? A review of literature. / Alongi, Filippo; Arcangeli, Stefano; De Bari, Berardino; Giaj-Levra, Niccolò; Fiorentino, Alba; Mazzola, Rosario; Trovò, Marco.
In: Critical Reviews in Oncology/Hematology, Vol. 112, 01.04.2017, p. 67-71.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Stage-I small cell lung cancer
T2 - A new potential option for stereotactic ablative radiation therapy? A review of literature
AU - Alongi, Filippo
AU - Arcangeli, Stefano
AU - De Bari, Berardino
AU - Giaj-Levra, Niccolò
AU - Fiorentino, Alba
AU - Mazzola, Rosario
AU - Trovò, Marco
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.
AB - Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.
KW - Outcomes
KW - Small cell lung cancer
KW - Stereotactic ablative radiotherapy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85015664635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015664635&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2017.02.010
DO - 10.1016/j.critrevonc.2017.02.010
M3 - Review article
C2 - 28325266
AN - SCOPUS:85015664635
VL - 112
SP - 67
EP - 71
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -